<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">37022974</PMID><DateCompleted><Year>2023</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>10</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1545-861X</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>14</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>MMWR. Morbidity and mortality weekly report</Title><ISOAbbreviation>MMWR Morb Mortal Wkly Rep</ISOAbbreviation></Journal><ArticleTitle>Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022.</ArticleTitle><Pagination><StartPage>366</StartPage><EndPage>371</EndPage><MedlinePgn>366-371</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.15585/mmwr.mm7214a3</ELocationID><Abstract><AbstractText>Circulating vaccine-derived poliovirus (cVDPV) outbreaks* can occur when oral poliovirus vaccine (OPV, containing one or more Sabin-strain serotypes 1, 2, and 3) strains undergo prolonged circulation in under-vaccinated populations, resulting in genetically reverted neurovirulent virus (1,2). Following declaration of the eradication of wild poliovirus type 2 in 2015 and the global synchronized switch from trivalent OPV (tOPV, containing Sabin-strain types 1, 2, and 3) to bivalent OPV (bOPV, containing types 1 and 3 only) for routine immunization activities<sup>†</sup> in April 2016 (3), cVDPV type 2 (cVDPV2) outbreaks have been reported worldwide (4). During 2016-2020, immunization responses to cVDPV2 outbreaks required use of Sabin-strain monovalent OPV2, but new VDPV2 emergences could occur if campaigns did not reach a sufficiently high proportion of children. Novel oral poliovirus vaccine type 2 (nOPV2), a more genetically stable vaccine than Sabin OPV2, was developed to address the risk for reversion to neurovirulence and became available in 2021. Because of the predominant use of nOPV2 during the reporting period, supply replenishment has frequently been insufficient for prompt response campaigns (5). This report describes global cVDPV outbreaks during January 2021-December 2022 (as of February 14, 2023) and updates previous reports (4). During 2021-2022, there were 88 active cVDPV outbreaks, including 76 (86%) caused by cVDPV2. cVDPV outbreaks affected 46 countries, 17 (37%) of which reported their first post-switch cVDPV2 outbreak. The total number of paralytic cVDPV cases during 2020-2022 decreased by 36%, from 1,117 to 715; however, the proportion of all cVDPV cases that were caused by cVDPV type 1 (cVDPV1) increased from 3% in 2020 to 18% in 2022, including the occurrence of cocirculating cVDPV1 and cVDPV2 outbreaks in two countries. The increased proportion of cVDPV1 cases follows a substantial decrease in global routine immunization coverage and suspension of preventive immunization campaigns during the COVID-19 pandemic (2020-2022) (6); outbreak responses in some countries were also suboptimal. Improving routine immunization coverage, strengthening poliovirus surveillance, and conducting timely and high-quality supplementary immunization activities (SIAs) in response to cVDPV outbreaks are needed to interrupt cVDPV transmission and reach the goal of no cVDPV isolations in 2024.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bigouette</LastName><ForeName>John Paul</ForeName><Initials>JP</Initials></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Traoré</LastName><ForeName>Mohamed A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Wassilak</LastName><ForeName>Steven G F</ForeName><Initials>SGF</Initials></Author><Author ValidYN="Y"><LastName>Jorba</LastName><ForeName>Jaume</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mahoney</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Bolu</LastName><ForeName>Omotayo</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Diop</LastName><ForeName>Ousmane M</ForeName><Initials>OM</Initials></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Cara C</ForeName><Initials>CC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>MMWR Morb Mortal Wkly Rep</MedlineTA><NlmUniqueID>7802429</NlmUniqueID><ISSNLinking>0149-2195</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="Y">Disease Outbreaks</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="Y">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017955" MajorTopicYN="N">Poliovirus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="Y">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>4</Month><Day>10</Day><Hour>10</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>6</Day><Hour>13</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37022974</ArticleId><ArticleId IdType="pmc">PMC10078846</ArticleId><ArticleId IdType="doi">10.15585/mmwr.mm7214a3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: delivering on a promise. Geneva, Switzerland: World Health Organization; 2021. https://polioeradication.org/gpei-strategy-2022-2026/</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. Standard operating procedures: responding to a poliovirus event or outbreak, version 4. Geneva, Switzerland: World Health Organization; 2020. https://www.who.int/publications/i/item/9789240049154</Citation></Reference><Reference><Citation>Global Polio Eradication Initiative. OPV cessation. Geneva, Switzerland: World Health Organization; 2023. https://polioeradication.org/polio-today/preparing-for-a-polio-free-world/opv-cessation/</Citation></Reference><Reference><Citation>Alleman MM, Jorba J, Henderson E, et al. Update on vaccine-derived poliovirus outbreaks—worldwide, January 2020–June 2021. MMWR Morb Mortal Wkly Rep 2021;70:1691–9. 10.15585/mmwr.mm7049a1</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7049a1</ArticleId><ArticleId IdType="pmc">PMC8659190</ArticleId><ArticleId IdType="pubmed">34882653</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Polio Eradication Initiative. cVDPV2 outbreaks and the type 2 novel oral polio vaccine (nOPV2). Geneva, Switzerland: World Health Organization; 2022. https://polioeradication.org/wp-content/uploads/2022/10/GPEI-nOPV2-Factsheet-EN-20221011.pdf</Citation></Reference><Reference><Citation>Rachlin A, Danovaro-Holliday MC, Murphy P, Sodha SV, Wallace AS. Routine vaccination coverage—worldwide, 2021. MMWR Morb Mortal Wkly Rep 2022;71:1396–400. 10.15585/mmwr.mm7144a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144a2</ArticleId><ArticleId IdType="pmc">PMC9639437</ArticleId><ArticleId IdType="pubmed">36327156</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson AL, Diop OM, Jorba J, Gardner T, Snider CJ, Ahmed J. Surveillance to track progress toward polio eradication—worldwide, 2020–2021. MMWR Morb Mortal Wkly Rep 2022;71:538–44. 10.15585/mmwr.mm7115a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7115a2</ArticleId><ArticleId IdType="pmc">PMC9020859</ArticleId><ArticleId IdType="pubmed">35421079</ArticleId></ArticleIdList></Reference><Reference><Citation>Rachlin A, Patel JC, Burns CC, et al. Progress toward polio eradication—worldwide, January 2020–April 2022. MMWR Morb Mortal Wkly Rep 2022;71:650–5. 10.15585/mmwr.mm7119a2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7119a2</ArticleId><ArticleId IdType="pmc">PMC9098249</ArticleId><ArticleId IdType="pubmed">35552352</ArticleId></ArticleIdList></Reference><Reference><Citation>Davlantes E; Malawi Ministry of Health; Global Polio Eradication Initiative. Notes from the field: initial outbreak response activity following wild poliovirus type 1 detection—Malawi, February 2022. MMWR Morb Mortal Wkly Rep 2022;71:776–7. 10.15585/mmwr.mm7123a3</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7123a3</ArticleId><ArticleId IdType="pmc">PMC9181050</ArticleId><ArticleId IdType="pubmed">35679180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryerson AB, Lang D, Alazawi MA, et al. Wastewater testing and detection of poliovirus type 2 genetically linked to virus isolated from a paralytic polio case—New York, March 9–October 11, 2022. MMWR Morb Mortal Wkly Rep 2022;71:1418–24. 10.15585/mmwr.mm7144e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7144e2</ArticleId><ArticleId IdType="pmc">PMC9639435</ArticleId><ArticleId IdType="pubmed">36327157</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>